Grosse-Hovest L - Search Results

1

Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia.

Schmiedel BJ, Werner A, Steinbacher J, Nuebling T, Buechele C, Grosse-Hovest L, Salih HR. Schmiedel BJ, et al. Mol Ther. 2013 Apr;21(4):877-86. doi: 10.1038/mt.2013.11. Epub 2013 Feb 5. Mol Ther. 2013. PMID: 23380816 Free PMC article.

2

Role of target antigen in bispecific-antibody-mediated killing of human glioblastoma cells: a pre-clinical study.

Pfosser A, Brandl M, Salih H, Grosse-Hovest L, Jung G. Pfosser A, et al. Int J Cancer. 1999 Feb 9;80(4):612-6. doi: 10.1002/(sici)1097-0215(19990209)80:4<612::aid-ijc21>3.0.co;2-k. Int J Cancer. 1999. PMID: 9935165

3

4-1BB ligand modulates direct and Rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia.

Buechele C, Baessler T, Schmiedel BJ, Schumacher CE, Grosse-Hovest L, Rittig K, Salih HR. Buechele C, et al. Eur J Immunol. 2012 Mar;42(3):737-48. doi: 10.1002/eji.201141920. Epub 2011 Dec 20. Eur J Immunol. 2012. PMID: 22144129 Free article.

4

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia.

Hofmann M, Große-Hovest L, Nübling T, Pyż E, Bamberg ML, Aulwurm S, Bühring HJ, Schwartz K, Haen SP, Schilbach K, Rammensee HG, Salih HR, Jung G. Hofmann M, et al. Leukemia. 2012 Jun;26(6):1228-37. doi: 10.1038/leu.2011.372. Epub 2012 Jan 6. Leukemia. 2012. PMID: 22289926

5

Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses.

Hilpert J, Grosse-Hovest L, Grünebach F, Buechele C, Nuebling T, Raum T, Steinle A, Salih HR. Hilpert J, et al. J Immunol. 2012 Aug 1;189(3):1360-71. doi: 10.4049/jimmunol.1200796. Epub 2012 Jun 22. J Immunol. 2012. PMID: 22730533

6

RANKL expression, function, and therapeutic targeting in multiple myeloma and chronic lymphocytic leukemia.

Schmiedel BJ, Scheible CA, Nuebling T, Kopp HG, Wirths S, Azuma M, Schneider P, Jung G, Grosse-Hovest L, Salih HR. Schmiedel BJ, et al. Cancer Res. 2013 Jan 15;73(2):683-94. doi: 10.1158/0008-5472.CAN-12-2280. Epub 2012 Nov 8. Cancer Res. 2013. PMID: 23139212

7

Receptor activator for NF-κB ligand in acute myeloid leukemia: expression, function, and modulation of NK cell immunosurveillance.

Schmiedel BJ, Nuebling T, Steinbacher J, Malinovska A, Wende CM, Azuma M, Schneider P, Grosse-Hovest L, Salih HR. Schmiedel BJ, et al. J Immunol. 2013 Jan 15;190(2):821-31. doi: 10.4049/jimmunol.1201792. Epub 2012 Dec 14. J Immunol. 2013. PMID: 23241893

8

A "vicious cycle" of NK-cell immune evasion in acute myeloid leukemia mediated by RANKL?

Schmiedel BJ, Grosse-Hovest L, Salih HR. Schmiedel BJ, et al. Oncoimmunology. 2013 May 1;2(5):e23850. doi: 10.4161/onci.23850. Oncoimmunology. 2013. PMID: 23762785 Free PMC article.

9

An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.

Steinbacher J, Baltz-Ghahremanpour K, Schmiedel BJ, Steinle A, Jung G, Kübler A, André MC, Grosse-Hovest L, Salih HR. Steinbacher J, et al. Int J Cancer. 2015 Mar 1;136(5):1073-84. doi: 10.1002/ijc.29083. Epub 2014 Jul 28. Int J Cancer. 2015. PMID: 25046567

10

Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.

Raab S, Steinbacher J, Schmiedel BJ, Kousis PC, Steinle A, Jung G, Grosse-Hovest L, Salih HR. Raab S, et al. J Immunol. 2014 Oct 15;193(8):4261-72. doi: 10.4049/jimmunol.1400872. Epub 2014 Sep 12. J Immunol. 2014. PMID: 25217158

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters